Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
"Our presence at this year's ASCO reinforces our progress toward delivering a breakthrough personalized cell therapy for patients with refractory hematological malignancies who have limited or no treatment options," said
Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. "These data represent a key milestone in our trajectory to advance personalized T cell immuno-oncology and ultimately address critical unmet medical needs."
Data to be presented include results from Kite's SCHOLAR-1 study, the first and largest meta-analysis of outcomes in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL). Patients with chemorefractory DLBCL have not responded to prior treatment with chemotherapy or have relapsed within a year after autologous stem cell transplantation.
Data from a Phase 1-2a study evaluating anti-CD19 CAR T cell therapy
after low-dose chemotherapy in people with advanced lymphoma will be
presented in a Late-Breaking Abstract oral session by James N.
Kochenderfer, M.D., an investigator in the Experimental Transplantation
and Immunology Branch of the
Kite will also provide an update on patients with chemorefractory
aggressive
Presentations at the 2016 ASCO Annual Meeting:
Oral Presentation
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma
Date:
Location:
Hall D2
Abstract Number: LBA3010
Presenter:
James Kochenderfer, M.D., Experimental Transplantation and Immunology
Branch,
Poster Discussion
Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): results from the international SCHOLAR-1 Study
Date:
Location:
E354b
Abstract Number: 7516
Presenter:
Michael Crump, M.D., FRCPC,
Poster Presentations
Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL)
Date:
Location:
Poster Board 115, Hall A
Abstract Number: 7559
Presenter:
Sattva Swarup Neelapu, M.D.,
ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)
Date:
Location:
Poster Board 65a, Hall A
Abstract Number: TPS7075
Presenter:
Alan S. Wayne, M.D., Children's Hospital Los Angeles,
About Kite Pharma
About Kite's ZUMA Clinical Programs for KTE-C19
KTE-C19 is an investigational therapy in which a patient's T cells are
genetically modified to express a CAR that is designed to target the
antigen CD19, a protein expressed on the cell surface of B-cell
lymphomas and leukemias. Kite is currently enrolling four pivotal
studies (also known as ZUMA studies) for KTE-C19 in patients with
various B-cell malignancies. The
Study | Phase | Indication | Status | |||
ZUMA-1 NCT02348216 |
Phase 2 Pivotal (N=112) |
Refractory DLBCL, PMBCL, TFL | Phase 2 enrolling | |||
ZUMA-2 NCT02601313 |
Phase 2 Pivotal (N=70) |
Relapsed/refractory MCL | Phase 2 enrolling | |||
ZUMA-3 NCT02614066 |
Phase 1/2 Pivotal (N=75) |
Relapsed/refractory Adult ALL | Phase 1/2 enrolling | |||
ZUMA-4
NCT02625480 |
Phase 1/2 Pivotal (N=75) |
Relapsed/refractory Pediatric ALL | Phase 1/2 enrolling | |||
DLBCL = diffuse large B-cell lymphoma | ||||||
PMBCL = primary mediastinal B-cell lymphoma | ||||||
TFL = transformed follicular lymphoma | ||||||
MCL = mantle cell lymphoma | ||||||
ALL = acute lymphoblastic leukemia | ||||||
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should" or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to advance multiple clinical
trials of KTE-C19, and the ability and willingness of the NCI to
continue research and development activities pursuant to the CRADA.
Various factors may cause differences between Kite's expectations and
actual results as discussed in greater detail in Kite's filings with the
Комментарии